<DOC>
	<DOC>NCT02275312</DOC>
	<brief_summary>The objective of this study is to evaluate the effectiveness of BoNT-A on functional improvement in patients with post-stroke upper and/or lower limb spasticity in the early stage of spasticity development, according to routine clinical practice.</brief_summary>
	<brief_title>ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Men and women â‰¥ 1880 years. Poststroke limb spasticity. Patients who have suffered a stroke in the previous 6 months. Treatment goal has been previously agreed with the patient or their legal representative. Patients with clinically significant poststroke upper/lower limb spasticity, in whom it has been decided to perform multidisciplinary treatment with BoNTA + rehabilitation. No previous treatment with BoNTA. Patient is able to follow the protocol. Written informed consent. Neuromuscular disease. Use of drugs that interfere with neuromuscular transmission. Any other condition that could interfere with rehabilitation or evaluation of the results. Diagnosis of spasticity not associated with stroke. Pregnant or nursing mothers. Prior participation in any other study in the 6 months before study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>